

◆Annual Meeting News

JSMO2026 information

<The 23rd Annual Meeting of JSMO (JSMO2026) >

- Theme: Medical Oncologists for Cancer Patients
- Date: Thursday, March 26 – Saturday, 28, 2026
- Place: Pacifico Yokohama
- President: Kenji Tamura, M.D., Ph.D.
Professor, Department of Medical Oncology, Shimane University Hospital
- Web Site: <https://www.congre.co.jp/jsmo2026/en/>
- Congress Secretariat: jsmo2026@congre.co.jp

Important Day

<Abstract Submission>

June 12th (Thu.) - September 17th (Wed.), 2025

Abstract Submission guidelines will be released around early June, 2025.

Please check the updates on "Call for Abstracts" page of the JSMO2026 website.

===== Website page of Call for Abstracts =====

<https://www.congre.co.jp/jsmo2026/en/cfa.html>

Inquiries for Abstract Submission: jsmo2026-abs@congre.co.jp

Message from the Congress President (JSMO2026)

We are pleased to announce that the 23rd Annual Meeting of the Japanese Breast Cancer Society (JSMO2026) will be held over three days from Thursday, March 26, to Saturday, March 28, 2026, at PACIFICO Yokohama North and Exhibition Hall D (Yokohama, Japan). The theme of this meeting is "Medical Oncologists for Cancer Patients".

Since 2006, JSMO has been conducting board certification in medical oncology. In 2026, the program will mark its 20th anniversary, having training around 2,000 medical oncologists in Japan. This significant occasion provides an opportunity to explore the ideal role of the "Medical Oncologist". We will examine their contributions to cancer treatment and research, their role in standardizing cancer care, and their involvement in team-based approaches. Additionally, we aim to consider cancer patients' perspectives, the required number of specialists, regional and institutional disparities, and issues related to domestic and international board certification systems. Through these discussions, we hope to clarify the future direction of board certification in medical oncology.

JSMO2026 will also focus on "Asian Oncology," highlighting contributions from Asia regarding clinical oncology for cancer treatment. We aim to revisit the history of outstanding basic research and novel evidence on anti-cancer drug development originating from Asian countries, including Japan, across various cancer fields. Furthermore, we will explore the future of collaborative research in Asia, and address opportunities for oncologic education as well as the relationships among young oncologists in the region.

In addition, JSMO2026 will showcase the latest high-level evidence in oncology, fostering in-depth discussions during the meeting. We look forward to receiving numerous general abstract submissions on these subjects from both domestic and international participants. Through active discussions on the latest evidence, we aim to further promote international collaboration and advancements in the field.

The meeting will also cover various topics, such as anti-cancer drug development, cancer genome medicine, personalized medicine, perioperative chemotherapy, and cancer care tailored to different life stages (including pediatrics, the AYA generation, and elderly cancer patients). Additional topics include onco-fertility, hereditary tumors, and the intersection of cancer care with patients, their families, and society.

Late March in Japan is typically a season of pleasant weather, with cherry blossoms in full bloom. We hope that many colleagues from both Japan and overseas will join us, enriching academic discussions and enjoying the scenic views and culinary delights of the port city of Yokohama.

We look forward to welcoming you and sharing this meaningful occasion together.

Sincerely,